AzTrials
AzTrials

Shellfish AllergySWAPNCT02151279

Safety of Chitosan as Wine Fining Agent in Shrimp Allergic Patients

A study testing Chitosan as wine fining agent in people with Shellfish Allergy, run by Universidade do Porto at 2 sites in Portugal.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Chitosan, the main component of the exoskeletons of crustaceans, mollusks and cephalopods, has been used as a fining agent in wines. However, its safety among patients allergic to shellfish has never been evaluated. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Shellfish Allergy
What is being tested?
Chitosan as wine fining agent
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
15 participants
Where
2 sitesPortugal
Study dates
Mar 2014to Sep 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged above 18 and less than 65 years
  • Willing to comply with all study procedures and available for the duration of the study;
  • Diagnosed with shrimp allergy, based on clinical history, plus positive skin tests and/or positive IgE;
  • Previous anaphylactic reaction to shrimp;
  • Either sex and of any race
  • Provide signed and dated informed consent form

Who cannot join

  • Dermatological disease which precludes or alters the results of skin tests
  • History of wine/alcohol intolerance
  • Acquired or hereditary immunodeficiency
  • Neoplasia
  • Psychiatric disease
  • FEV1<70%
Show all 10Show fewer
  • Taking any systemic medication that might interfere with the study and that is not possible to withdraw, namely oral corticosteroids or immunomodulators in the last 4 weeks, or antihistamines in the last 10 days
  • Under beta-blockers or ACE inhibitors
  • Presence of any significant illness that could interfere with the study or alter its results or increase the risk of anaphylaxis, such as systemic mastocytosis
  • Pregnancy or lactation

Trial locations and contacts

2 sites in 1 country.

Luís P Amaral, MD contact

+35122 551 2100

luis.m.amaral@gmail.com

Portugal2 sites, 2 recruiting
  • Universidade de Aveiro

    Aveiro

    Manuel A Coimbra, PhD

    Silvia M Rocha, PhD

    Recruiting
  • Serviço de Imunoalergologia Hospital São João

    Porto, 4200-239

    Luis P Amaral, MD, +351 5512100, luis.m.amaral@gmail.com

    Luis P Amaral, MD

    Recruiting

Other trials in Portugal

About this study

Chitosan, the main component of the exoskeletons of crustaceans, mollusks and cephalopods, has been used as a fining agent in wines. However, its safety among patients allergic to shellfish has never been evaluated.

Adult patients followed at the Allergy and Clinical Immunology Department who have been diagnosed with anaphylaxis to shrimp will be invited to participate in the study.

Read more

Clinical data will be collected to ascertain for eligibility and written information will be provided. After signing informed consent, included subjects will perform skin prick-to-prick tests (PTP) with shrimp boiling water condensate and with fined and unfined wines. All will perform double blind oral challenge with the fined and unfined wines during 1visit day; the placebo (unfined wine) and active challenge (fined wine with chitosan) will be separated by 2 hours. Challenge protocol will be performed with successive increasing doses administered in 4 steps at 15-minute intervals for a total of 100 mL. During the challenge signs and symptoms will be monitored by a trained physician.

Results will be presented as negative or positive (defined by presence of symptoms and signs of an allergic reaction).

Categorical data will be compared by chi-square test. P<0.05 will be considered statistically significant.

Read the detailed description

Hypersensitivity reactions to wine have been rarely reported in the literature, and they are mainly attributed to grape proteins [1], biogenic amines, salicylates, sulfites or yeast [2,3]. However, wine production traditionally involves fining, during which some ingredients such as tannins are removed by co-precipitation with proteins derived from milk (casein, potassium caseinate), egg (ovalbumin, lysozyme), fish (isinglass) or shrimp (chitosan). These proteins are derived from animal sources which are known to play a role in food allergy. This is an increasingly prevalent health problem in Western countries [4,5] and it may manifest itself as life-threatening anaphylactic shock in the presence of only traces of the allergen. Recently, the safety for wine-fining agents derived from milk, fish and egg was established [6]. However, for chitosan, no studies of its safety as a fining agent in allergic patients were performed until now. Chitosan is used as fining agent by the mead and wine industry because of its electrostatic positive charge. Chitosan is obtained by the deacetylation of Chitin [C8H13NO5N]n , a derivative of glucose, and one of the most common polymers found in nature. It is the main component of the cell walls of some fungi, the exoskeletons of arthropods such as crustaceans and insects, the radulae of mollusks, and the beaks of cephalopods, including squid and octopuses [7].

Seafood plays an important role in human nutrition and health, and Portugal is the European country with the second highest consumption [4]. The prevalence of crustacean allergy seems to vary largely between geographical locations, but it seems common in Portugal [8]. The major shellfish allergen is tropomyosin although other allergens may play an important part in allergenicity. The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions. Our aim is, therefore, to establish the safety of wine containing chitosan in patients who are severely allergic to shrimp [9].

Potential Risks Several studies published in the literature have evaluated the safety of skin tests, but mostly using commercial extracts. Prick-tests to native foods, called prick-to-prick tests, have been less extensively studied. The CICBAA1 data, from 1,138 food allergic patients of all ages, cover 34,905 prick-to-prick tests to foods. The risk of systemic reactions was evaluated at 0.008% [10, 11]. The negative predictive accuracy for skin prick testing to foods is uniformly high. A negative skin test confirms the absence of an IgE-mediated reaction with 90 to 95% accuracy [12,13]. Therefore, skin testing is highly useful for excluding IgE-mediated food allergy.

However, when positive, these tests, which evaluate sensitization and not clinical allergy, are not without pitfalls, and their results must be confirmed by an oral challenge to avoid over- and under diagnosis.

The double-blind, placebo-controlled, oral food challenge (DBPCFC) is considered the gold standard for diagnosing food allergy and it is preferred for research purposes [14]. The overall level of risk associated with food challenges has been examined. A retrospective series reviewed 584 OFCs performed in children who were estimated to have a ≤50% risk of reaction. Forty-three percent of the challenges were positive. Thirty-nine percent of the reactions were mild, 33% moderate, and 28% severe. The type and incidence of the different reactions were cutaneous (78%), gastrointestinal (43%), oral (26%), lower respiratory (26%), and upper respiratory (25%). No patients had cardiovascular symptoms [15].

Participants with positive and negative skin tests will proceed to oral challenge, as sensitization does not have a linear correlation with clinical allergy. Although the risk of a positive reaction to oral challenge with finned wine with chitosan is very low (severe seafood allergy is usually mediated by major shellfish allergen tropomyosin, not present in chitosan), for safety purposes the challenges will be performed in an appropriate setting, with CPR support available, medication and a doctor present at all times.

Potential Benefits It will allow for patients with shellfish allergy to be informed if they can safely ingest this wine. Furthermore, it will be needed as a public health measure as this information could be included in the wine labels.

STUDY OBJECTIVES

To investigate the safety of chitosan, as wine fining agent, in patients with severe allergy to shrimp.

Primary Outcome: Result of a DBPCFC with chitosan fined wine.

Being tested
Chitosan as wine fining agent, Control
Keywords
Shrimp allergy, Chitosan, fining agent
Medical subject headings
Shellfish Hypersensitivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Chitosan as wine fining agentOther

    The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.

  • ControlOther

Study groups in NCT02151279
Study groupRoleWhat they receive
control groupPlacebo comparatorChitosan as wine fining agent
Receives: Other: Control
Shrimp allergic patientsActive comparatorChitosan as wine fining agent
Receives: Other: Chitosan as wine fining agent

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants with adverse events to a Double Blind Placebo Controlled Food Challenge with chitosan fined wine

    Measured: Participants will be followed until one to two hours after the end of the Food Challenge, an expected average of 6 to 8 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 May 2014 (estimated)
  2. Study startMar 2014
  3. Primary completionJul 2014 (estimated)
  4. Study completionSep 2014 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02151279
Sponsor's protocol ID
SWAP study
Acronym
SWAP
Status last verified
May 2014
First submitted
20 May 2014
Last updated
30 May 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Amaral L, Silva D, Couto M, Nunes C, Rocha SM, Coimbra MA, Coimbra A, Moreira A. Safety of chitosan processed wine in shrimp allergic patients. Ann Allergy Asthma Immunol. 2016 May;116(5):462-3. doi: 10.1016/j.anai.2016.02.004. Epub 2016 Mar 19. No abstract available.

    PubMed 27009439

Questions about this trial

What is this clinical trial studying?

A study testing Chitosan as wine fining agent in people with Shellfish Allergy, run by Universidade do Porto at 2 sites in Portugal.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 May 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Luís P Amaral, MD (+35122 551 2100, luis.m.amaral@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants with adverse events to a Double Blind Placebo Controlled Food Challenge with chitosan fined wine (time frame: Participants will be followed until one to two hours after the end of the Food Challenge, an expected average of 6 to 8 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02151279, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in